⌘K
Loading ticker…
Impact BioMedical, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Impact BioMedical, Inc. (IBO) has a 3-month relative strength percentile of 20 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 40. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.7%, relative volume 0.33×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
20 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
IBO is held by 2 ETFs as of Mar 2026. Top owner: VXF at 0.00% weight, $424K notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $424K |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $4 |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IBO Jan avg: 8.86% median: 8.86% win: 50% σ: 16.73% n: 2 2024-09-17 → 2026-05-29 | IBO Feb avg: -10.44% median: -10.44% win: 0% σ: 1.03% n: 2 2024-09-17 → 2026-05-29 | IBO Mar avg: -3.55% median: -3.55% win: 50% σ: 58.53% n: 2 2024-09-17 → 2026-05-29 | IBO Apr avg: -18.79% median: -18.79% win: 50% σ: 45.43% n: 2 2024-09-17 → 2026-05-29 | IBO May avg: -1.34% median: -1.34% win: 50% σ: 31.38% n: 2 2024-09-17 → 2026-05-29 | IBO Jun avg: 25.43% median: 25.43% win: 100% σ: 0.00% n: 1 2024-09-17 → 2026-05-29 (current) | IBO Jul avg: -5.67% median: -5.67% win: 0% σ: 0.00% n: 1 2024-09-17 → 2026-05-29 | IBO Aug avg: -5.04% median: -5.04% win: 0% σ: 0.00% n: 1 2024-09-17 → 2026-05-29 | IBO Sep avg: -5.35% median: -5.35% win: 50% σ: 28.32% n: 2 2024-09-17 → 2026-05-29 | IBO Oct avg: -3.50% median: -3.50% win: 50% σ: 22.63% n: 2 2024-09-17 → 2026-05-29 | IBO Nov avg: 6.56% median: 6.56% win: 50% σ: 32.83% n: 2 2024-09-17 → 2026-05-29 | IBO Dec avg: -18.56% median: -18.56% win: 50% σ: 44.95% n: 2 2024-09-17 → 2026-05-29 |